World first: Launch of Quebec registry for users of medical cannabis
MUHC researcher heads one of the largest studies ever conducted on medical cannabis
“This registry has been developed to address the lack of research data on the safety and efficacy of cannabis,” states principal investigator Dr. Mark Ware, Director of Clinical Research of the Alan Edwards Pain Management Unit at the MUHC and associate professor in Family Medicine and Anesthesia at McGill University. “We need this database to help develop and answer future questions on the medical use of cannabis, such as who uses it, for what reasons, through which methods, and at what dose.”
The Quebec Cannabis Registry will be used to compile and store clinical data collected directly from patients who use medical marijuana. The data will be gathered from sites and clinics across Quebec, and each participant will provide data for four years after recruitment. Any licensed doctor practising in the province wishing to authorise cannabis for their adult patients can enrol participants in the registry.
Health Canada estimates that over 40,000 Canadians legally consume cannabis to relieve symptoms from such diseases as multiple sclerosis, HIV, cancer or epilepsy.
“We need to improve our understanding of the real-world use of medical cannabis and to make these data available to other researchers and collaborators,” explains Dr. Ware. “This is the first registry of cannabis users that has been designed to stimulate research and to broaden our knowledge of this field. The registry will eventually help us better understand the possible risks and benefits related to the use of this product.”
Most read news
Other news from the department science
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.